Tue, April 19, 2022
Mon, April 18, 2022
Sun, April 17, 2022
Thu, April 14, 2022
Wed, April 13, 2022
Tue, April 12, 2022
Mon, April 11, 2022
Sun, April 10, 2022
Fri, April 8, 2022

David Lebowitz Maintained (BPMC) at Hold with Decreased Target to $68 on, Apr 13th, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. ith-decreased-target-to-68-on-apr-13th-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Lebowitz of Citigroup, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Decreased Target from $71 to $68 on, Apr 13th, 2022.

David has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Decreased Target to $92 on, Tuesday, February 1st, 2022


These are the ratings of the 3 analyists that currently disagree with David


  • Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022
  • Michael Schmitz of "Guggenheim" Maintained at Strong Buy with Increased Target to $122 on, Monday, January 3rd, 2022

Publication Contributing Sources